Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × trastuzumab biosimilar HLX02 × Clear all

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms